Bokf Na Sells 3,357 Shares of Biogen Inc. (NASDAQ:BIIB)

BOKF NA decreased its stake in Biogen Inc. (NASDAQ:BIIB - Free Report) by 13.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 20,852 shares of the biotechnology company's stock after selling 3,357 shares during the period. BOKF NA's holdings in Biogen were worth $3,103,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Brevan Howard Capital Management LP grew its holdings in Biogen by 564.6% in the fourth quarter. Brevan Howard Capital Management LP now owns 7,138 shares of the biotechnology company's stock valued at $1,092,000 after purchasing an additional 6,064 shares during the last quarter. Captrust Financial Advisors grew its stake in Biogen by 49.6% in the 4th quarter. Captrust Financial Advisors now owns 9,712 shares of the biotechnology company's stock valued at $1,485,000 after acquiring an additional 3,218 shares during the last quarter. Cary Street Partners Financial LLC purchased a new position in Biogen during the 4th quarter valued at about $266,000. Brown Advisory Inc. raised its position in Biogen by 4.3% during the fourth quarter. Brown Advisory Inc. now owns 347,566 shares of the biotechnology company's stock worth $53,150,000 after acquiring an additional 14,339 shares during the last quarter. Finally, BNP Paribas lifted its holdings in shares of Biogen by 14.9% in the fourth quarter. BNP Paribas now owns 804 shares of the biotechnology company's stock valued at $123,000 after purchasing an additional 104 shares in the last quarter. Hedge funds and other institutional investors own 87.93% of the company's stock.

Biogen Price Performance

Shares of BIIB stock traded down $0.19 during mid-day trading on Friday, hitting $118.20. 1,306,483 shares of the stock traded hands, compared to its average volume of 1,368,989. The company has a debt-to-equity ratio of 0.27, a quick ratio of 0.90 and a current ratio of 1.35. The firm has a market cap of $17.32 billion, a price-to-earnings ratio of 10.56, a price-to-earnings-growth ratio of 1.51 and a beta of 0.12. The company's 50-day simple moving average is $128.33 and its 200-day simple moving average is $144.38. Biogen Inc. has a twelve month low of $110.04 and a twelve month high of $238.00.

Biogen (NASDAQ:BIIB - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The biotechnology company reported $3.02 EPS for the quarter, missing the consensus estimate of $3.26 by ($0.24). Biogen had a return on equity of 14.98% and a net margin of 16.87%. The business had revenue of $2.43 billion during the quarter, compared to the consensus estimate of $2.25 billion. During the same quarter last year, the firm posted $3.67 earnings per share. Biogen's revenue was up 6.2% compared to the same quarter last year. As a group, equities research analysts expect that Biogen Inc. will post 15.83 earnings per share for the current year.

Insiders Place Their Bets

In other Biogen news, Director Stephen A. Sherwin sold 8,760 shares of the business's stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $150.02, for a total transaction of $1,314,175.20. Following the sale, the director now owns 11,318 shares in the company, valued at approximately $1,697,926.36. The trade was a 43.63 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.16% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research analysts recently issued reports on the company. Bank Of America (Bofa) cut their price objective on Biogen from $178.00 to $163.00 and set a "neutral" rating for the company in a research report on Tuesday, February 11th. Mizuho cut their price target on Biogen from $207.00 to $169.00 and set an "outperform" rating for the company in a report on Wednesday. Needham & Company LLC reaffirmed a "hold" rating on shares of Biogen in a research note on Friday, May 2nd. JPMorgan Chase & Co. cut their target price on shares of Biogen from $185.00 to $175.00 and set a "neutral" rating for the company in a research note on Monday, May 5th. Finally, Royal Bank of Canada reduced their target price on shares of Biogen from $217.00 to $205.00 and set an "outperform" rating on the stock in a report on Friday, May 2nd. Twenty investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $191.30.

Biogen Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.